Caristo provides state of the art cardiac risk evaluation based on the analysis of standard CCTA scans, incorporating a personalized assessment of coronary inflammation, to help clinicians make more informed patient management decisions.
Can be applied to any routine clinical CCTA.
Analysis is performed using our patented, regulatory cleared platform, CaRi-Heart®.
Clinically demonstrated to improve discrimination of cardiac mortality prognosis over current risk assessment methods.
Registered in England and Wales under company number 11429590
CaRi-Heart® is limited to investigational use in the United States.
All contents of this website are copyright 2018 - 2021 Caristo Diagnostics Ltd. All rights reserved. No content may be copied or reproduced without the express permission of Caristo Diagnostics Ltd.
All copyright, trade-marks, design rights, database rights, patents and other intellectual property rights (registered and unregistered) in and on this website are owned by Caristo Diagnostics Ltd. and/or certain third parties.